Eikon Therapeutics Expands its Discovery Labs with Second Location in Hayward, California Portfolio News / By Karina Tin March 30, 2023 Eikon Therapeutics Expands its Discovery Labs with Second Location in Hayward, California Read More »
RAPT Therapeutics Announces Initiation of Phase 2A Trial of RPT193 in Patients with Moderate to Severe Asthma Portfolio News / By Karina Tin March 29, 2023 RAPT Therapeutics Announces Initiation of Phase 2A Trial of RPT193 in Patients with Moderate to Severe Asthma Read More »
Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer Portfolio News / By Karina Tin March 22, 2023 Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer Read More »
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress Portfolio News / By Karina Tin March 22, 2023 Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress Read More »
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 Portfolio News / By Karina Tin March 20, 2023 Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 Read More »
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting Portfolio News / By Karina Tin March 16, 2023 Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting Read More »
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Portfolio News / By Karina Tin March 16, 2023 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Read More »
RAPT Therapeutics Reports Fourth Quarter and Year End Financial Results Portfolio News / By Karina Tin March 14, 2023 RAPT Therapeutics Reports Fourth Quarter and Year End Financial Results Read More »
Ribon Therapeutics Doses First Patient In Phase 1 Clinical Study with RBN-3143 in Patients with Moderate to Severe Atopic Dermatitis Portfolio News / By Karina Tin March 9, 2023 Ribon Therapeutics Doses First Patient In Phase 1 Clinical Study with RBN-3143 in Patients with Moderate to Severe Atopic Dermatitis Read More »
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer Portfolio News / By Karina Tin March 8, 2023 eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer Read More »